Skip to main
BDTX
BDTX logo

BDTX Stock Forecast & Price Target

BDTX Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Black Diamond Therapeutics Inc. is advancing its pipeline with promising initial Phase 2 results for its fourth-generation EGFR MasterKey inhibitor, BDTX-1535, demonstrating a 36% overall response rate (ORR) among evaluable patients, which improves to 42% when excluding non-target resistance mutations. The company has shown that a significant 74% of patients remained on treatment during the data cut, indicating strong therapeutic potential in relapsed/refractory non-small cell lung cancer (NSCLC) with non-classical EGFR mutations, a market still underserved by current therapies. Additionally, updated data expected in 2025 from dose expansion cohorts may provide further validation of Black Diamond’s innovative approach and enhance the likelihood of favorable regulatory outcomes.

Bears say

Black Diamond Therapeutics Inc faces significant risks that contribute to a negative outlook, including potential negative efficacy data for its key drug candidate, BDTX-1535, and concerns regarding the safety profile of its pipeline treatments. Adjustments to near- to mid-term expense assumptions and commercialization timelines suggest a reduced financial trajectory, with a decrease in price target indicative of these challenges. For the fourth quarter of 2024, the company reported a net loss of $0.28 per share, aligning closely with previous estimates, but projections indicate a deeper full-year net loss of $1.32 for 2025, highlighting ongoing financial struggles.

BDTX has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Black Diamond Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Black Diamond Therapeutics (BDTX) Forecast

Analysts have given BDTX a Strong Buy based on their latest research and market trends.

According to 9 analysts, BDTX has a Strong Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $29.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $29.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Black Diamond Therapeutics (BDTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.